DBV Technologies
Country
France
Краткое название
DBV Technologies
Headquarters
Green Square - B^atiment D 80/84 rue des Meuniers
Members of the board
Dr Pierre-Henri Benhamou, Chief Executive Officer
Mr. Bertrand Dupont, Chief Technical Officer
Mr. David Schilansky, Chief Financial Officer
Mr. Charles Ruban, Chief Development Officer
Dr Laurent Martin, Regulatory Affairs Director
Dr Wence Agbotounou, Chief Clinical Trial Officer
Mr. Bertrand Dupont, Chief Technical Officer
Mr. David Schilansky, Chief Financial Officer
Mr. Charles Ruban, Chief Development Officer
Dr Laurent Martin, Regulatory Affairs Director
Dr Wence Agbotounou, Chief Clinical Trial Officer
Categories medicine
Allergy & Immunology
Stage of the project
Production
Disease
Anaphylactic collapse
Current owners
Mr. George Horner, Board member
Dr Pierre-Henri Benhamou, CEO, Chairman and Co-Founder
Dr. Torbjorn Bjerke, Karolinska Development
Mr. Peter Hutt, Covington & Burling LLP
Dr. Rafaele Tordjman, Partner Sofinnova
Ms. Chahra Louafi, InnoBio
Mr. Didier Hoch, Chairman of BioVision (The World Life Sciences Forum)
Ms. Mailys Ferrere, Investment Director for the FSI (Fonds Strategique d’Investissement)
Dr Pierre-Henri Benhamou, CEO, Chairman and Co-Founder
Dr. Torbjorn Bjerke, Karolinska Development
Mr. Peter Hutt, Covington & Burling LLP
Dr. Rafaele Tordjman, Partner Sofinnova
Ms. Chahra Louafi, InnoBio
Mr. Didier Hoch, Chairman of BioVision (The World Life Sciences Forum)
Ms. Mailys Ferrere, Investment Director for the FSI (Fonds Strategique d’Investissement)
Technology
Cell Technologies, Devices, Technologies, Pharmaceuticals